327 related articles for article (PubMed ID: 11653267)
1. The FDA's response to AIDS: paradigm shift in new drug policy?
Podraza R
Food Drug Law J; 1993; 48(3):351-75. PubMed ID: 11653267
[No Abstract] [Full Text] [Related]
2. Getting new drugs to people with AIDS: a public policy response to Lansdale.
Cohen MN
Hastings Constit Law Q; 1991; 18(3):471-85. PubMed ID: 11651493
[No Abstract] [Full Text] [Related]
3. Shaking up the status quo: how AIDS activists have challenged drug development and approval procedures.
Dunbar MM
Food Drug Cosmet Law J; 1991 Sep; 46(5):673-706. PubMed ID: 11651380
[No Abstract] [Full Text] [Related]
4. FDA's new rule on treatment use and sale of investigational new drugs.
Levine RJ
IRB; 1987; 9(4):1-4. PubMed ID: 11649946
[No Abstract] [Full Text] [Related]
5. AIDS treatment drugs: clinical trials and compassionate use.
Levine RJ
AIDS Public Policy J; 1987; 2(2):6-8. PubMed ID: 11650031
[No Abstract] [Full Text] [Related]
6. Considering experimentation and elusive truth: informed consent made difficult.
Brodeur D
Issues (St Louis Mo); 1992; 7(2):1-8. PubMed ID: 11659444
[No Abstract] [Full Text] [Related]
7. Protectionism and the new research imperative in pediatric AIDS.
Ackerman TF
IRB; 1990; 12(5):1-5. PubMed ID: 11654001
[No Abstract] [Full Text] [Related]
8. Informed consent: the FDA's perspective.
Bagley G
Food Drug Law J; 1993; 48(2):181-6. PubMed ID: 11653141
[No Abstract] [Full Text] [Related]
9. Experimental drugs: more of them, but they're no longer free.
Caplan J
Hastings Cent Rep; 1987 Jun; 17(3):3. PubMed ID: 11644019
[No Abstract] [Full Text] [Related]
10. Implications of the federal drug investigation and approval processes for the development and availability of AIDS treatments and vaccines.
Mathers PR
AIDS Public Policy J; 1987; 2(2):50-3. PubMed ID: 11650030
[No Abstract] [Full Text] [Related]
11. Women and HIV/AIDS research: the barriers to equity.
Levine C
IRB; 1991; 13(1-2):18-22. PubMed ID: 11659324
[No Abstract] [Full Text] [Related]
12. FDA treatment use regulations: a compassionate response.
Weitzman SA; Marcy T
AIDS Public Policy J; 1987; 2(2):22-32. PubMed ID: 11650028
[No Abstract] [Full Text] [Related]
13. Faith (healing), hope and charity at the FDA: the politics of AIDS drug trials.
Annas GJ
Villanova Law Rev; 1989 Sep; 34(5):771-97. PubMed ID: 11651162
[No Abstract] [Full Text] [Related]
14. AIDS study casts doubt on value of hastened drug approval in U.S.
Altman LK
N Y Times Web; 1993 Apr; ():C3. PubMed ID: 11646977
[No Abstract] [Full Text] [Related]
15. U.S. permits AIDS patients to use unproved drug.
Kolata G
N Y Times Web; 1989 Jan; ():A1, B6. PubMed ID: 11646713
[No Abstract] [Full Text] [Related]
16. New rules for new drugs: the challenge of AIDS to the regulatory process.
Edgar H; Rothman DJ
Milbank Q; 1990; 68(Suppl. 1):111-42. PubMed ID: 11650413
[TBL] [Abstract][Full Text] [Related]
17. Regulatory concerns regarding AIDS vaccine development.
Sawyer LA; Katzenstein DA; Quinnan GV
AIDS Public Policy J; 1988; 3(3):36-45. PubMed ID: 11650100
[No Abstract] [Full Text] [Related]
18. Cost of HIV drugs.
American Public Health Association
Am J Public Health; 1991 Feb; 81(2):250. PubMed ID: 11642863
[No Abstract] [Full Text] [Related]
19. Regulation of drug treatments for HIV and AIDS: a contractarian model of access.
Salbu SR
Yale J Regul; 1994; 11(2):401-53. PubMed ID: 11660141
[No Abstract] [Full Text] [Related]
20. FDA's compassion for desperate drug companies.
Annas GJ
Hastings Cent Rep; 1990; 20(1):35-7. PubMed ID: 2179165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
